Two high school students on Long Island are putting their language skills to good use to be kind and help people overcome language barriers when making appointments for a COVID vaccine.
Two high school students on Long Island are putting their language skills to good use to be kind and help people overcome language barriers when making appointments for a COVID vaccine.
It’s widely known that video streaming boomed during the pandemic, as millions of people were faced by boredom during lockdowns. Oddly enough this is also the pitch of the famed satirical show, Silicon Valley, where fictional startup PiedPiper invents a new creates an app that contains a revolutionary data compression algorithm for video.
The "Global Epoxy Resins Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
Executive Summary The Global Pet Market was valued at USD 223. 54 Billion in the year 2020. With the increased disposable income in highly populated countries such as China and India, the pet adoption rate is increasing and is expected to grow further in upcoming years.New York, May 06, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pet Market – Analysis By Type, Pet Type, By Distribution Channel, By Region, : Market Insights, Covid-19 Impact, Competition and Forecast" - https://www.reportlinker.com/p06067735/?utm_source=GNW The trends such as pet humanization and premiumization are driving the Pet market. In this era, people are inclining towards the culture of nuclear families and hence it is resulting in the demand for pet adoption as people have started accepting pets as their family members even in the developing countries.Dog is the most favourite pet to be adopted in the Pet market. The major factors influencing the growth of the global pet market are mobile pet grooming, strategic initiatives by the major market players, growing humanization and manufacturers opting for e-commerce channel. Currently, pet stores holds the larger market share in the segment of distribution channel as compared to e-commerce channel but, in upcoming years, e-commerce is expected to witness tremendous growth in pet market.North America region holds the major Pet market share and countries, such as United States and Canada, are the major contributors to the regional market. Increasing adoption of pets in the region, especially in United States, is the major growth-driving factor.Pet Care Products segment is expected to hold largest share of Pet market. It majorly includes the different kinds of pet care products available in the market attributing to number of benefits related to the daily activities of pets, health related concerns and other related things.Scope of the Report• The report analyses the Pet Market by value (USD Billion).• The report analyses the Pet Market by Type (Pet Food, Pet care Products, Pet Services).• The report analyses the Pet Market by Pet Type (Dog, Cat, Fish, Others).• The report analyses the Pet Market by Distribution Channel (E-commerce, Pet Stores).• The Global Pet Market has been analysed by countries (United States, Canada, United Kingdom, Germany, France, China, Japan, India, South Korea, Brazil).• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by type, by pet type, by distribution channel.• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include General Mills Incorporated, JM Smucker, Spectrum Brands, Unicharm Corporation, Nestle, Hill’s Pet Nutrition, Agrolimen SA, ADM Animal Nutrition, PetSmart,Mars Incorporated.• The report presents the analysis of Pet market for the historical period of 2016-2020 and the forecast period of 2021-2026.Key Target Audience• Pet Industry Players• Pet Food Companies• Consulting and Advisory Firms• Government and Policy Makers• Regulatory AuthoritiesRead the full report: https://www.reportlinker.com/p06067735/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
May 6—LINDSIDE — The James Monroe baseball team has taken some early lumps this season. Wednesday was relatively lump-less. Andrew Hazelwood had a solid day on the mound and at the plate and the Mavericks rolled to a 10-0 win over PikeView at James Monroe High School. A six-run JM rally in the bottom of the sixth inning called a close to the game, the redemption of which lingered tantalizingly ...
Economy expected to grow by 7.25% in 2021 as lockdown restrictions are eased, says Bank of England.
May 6—CHARLESTON — Sometimes one player can be a real pain. Ethan Payne patrolled the paint all evening and his consistency was enough to enable favored Poca to edge past a battling band of Bluefield Beavers, 49-42, in quarterfinal action of the 2021 West Virginia Secondary Schools Activities Commission tournament. Bluefield (9-10), which led briefly in the opening half on a Caleb Fuller trey, ...
The average bank stock was up 28% year to date at the end of April, and only a handful of other industries had higher average returns. The usual suspects -- Bank of America, JPMorgan Chase, Wells Fargo, and Citigroup, to name a few -- get most of the attention, and rightfully so. There are a lot of good bank stocks out there right now, but this is one of the best bank stocks that no one is talking about.
May 6—PORTAGE — The Portage Area High School softball team was rolling along before an unplanned hiatus in the schedule over the last week slowed its path toward a potential WestPAC championship and a high seed in the District 6 playoffs. "We had a little COVID adventure," Mustang shortstop Maddy Hudak said. "And then, obviously, the weather hasn't been the greatest. A lot of us weren't even ...
May 6—BRIDGEPORT — Senior midfielder Yasmin Mosby of the Concord University women's soccer team has been named the Mountain East Conference Offensive Player of the Year while a total of five Mountain Lions landed on the All-MEC Teams announced Wednesday afternoon by the league office. Mosby was joined on the All-MEC First Team by sophomore defender Zoe Belding, junior forward Leah Foster and ...
CONTROLTEK, a leading provider of tamper-evident cash security packaging, in partnership with Currency Research, the leading global resource for central banks, their suppliers, and the related supply chain for currency and payment systems, announces the launch of The Cash News, a podcast featuring the latest news about currency and issues affecting the world of cash today.
Atlantic Street Capital ("ASC"), a private equity firm targeting entrepreneurial businesses poised for the next level of growth, today announced that Johnny Conklin has joined the firm as a Partner. In this role, Mr. Conklin is responsible for the firm's deal sourcing team and business development strategy for new platforms and add-on acquisitions. In his role, Johnny collaborates with investment and operating partners, as well as portfolio company management teams on investment execution and strategic growth priorities.
Ever dreamed of driving an electric vehicle but felt like ownership was out of reach? Toronto-based electric car retailer, electric vehicle network (EV Network) has raised its first seed capital from investment firm, EV Angels to make electric car ownership more accessible for everyone.
EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it has completed recruitment for its Phase 2a ‘AMBITION’ clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled. “Over the past few months, the COVID-19 pandemic, compounded by the inclement weather experienced at some of our clinical trial sites in Texas, which resulted in power outages, presented difficulties in the recruitment of subjects for the second and final dosing cohort for our Phase 2a NASH trial,” said Dr. Robert Foster, Hepion’s CEO. “However, we were able to overcome these challenges and are pleased that AMBITION is now fully enrolled. After completion of 28 days dosing with either CRV431 or placebo, study subjects will be monitored for an additional 14 day period, during which time we will continue to collect data – focusing on CRV431’s safety, tolerability, pharmacokinetics and biomarker analyses for early assessments of efficacy.” “It is certainly rewarding for the Hepion clinical team to see the conclusion of enrollment for the AMBITION trial,” said Dr. Todd M. Hobbs, Hepion’s newly appointed Chief Medical Officer. “With their hard work and perseverance, we will soon be able to see a more complete picture of the safety, PK, and early efficacy of CRV431 in patients with NASH.” The Phase 2a ‘AMBITION’ study is a single-blinded, placebo controlled trial designed to assess safety, tolerability, pharmacokinetics, and biomarker analyses for early assessments of efficacy of 75 and 225 mg CRV431. Study drug or placebo are administered orally (n=18 subjects in each dosing cohort), once daily for 28 days. Hepion will also examine several biomarkers including collagens, matrix metalloproteinases, lipidomics, genomics, liver transaminases, Pro-C3, ELF score, gene-gene, gene-protein network analysis, and Fibroscan to determine early assessments of efficacy of CRV431 in the treatment of NASH. In addition, Hepion will use AI-POWR™, its proprietary Bioinformatics and AI platform that allows for precision medicine, to optimize the understanding the activity of CRV431 in NASH, which will also guide further development of CRV431 in subsequent clinical studies. About Hepion Pharmaceuticals The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect: (646) email@example.com
Globally Local Technologies Inc., ("the Company") (TSXV: GBLY), the parent company of Globally Local, one of the world's first vegan fast-food chains, announced today it is on track to open five new Ontario restaurant locations in the Summer 2021 timeframe.
“The industry has never seen a buyer acquire with such velocity in such a short period of time,” an industry M&A banker says.
CALGARY, Alberta, May 06, 2021 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to provide the following information concerning its April 2021 natural gas sales and drilling program. Gas sales averaged 166 MMscfpd for April 2021 Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 166 million standard cubic feet per day (“MMscfpd”) for April 2021. Nelson 9 development well and Agua Vivas 1 exploration well The Nelson 9 development well encountered 52 feet true vertical depth of gas pay within the Porquero sandstone target, and will be tied in and on production by early May 2021. The Aguas Vivas 1 exploration well is expected to spud prior to Mid May 2021. About Canacol Canacol is a natural gas exploration and production company with operations focused in Colombia. The Corporation's common stock trades on the Toronto Stock Exchange, the OTCQX in the United States of America, and the Colombia Stock Exchange under ticker symbol CNE, CNNEF, and CNE.C, respectively. This press release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur, including without limitation statements relating to estimated production rates from the Corporation's properties and intended work programs and associated timelines. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation cannot assure that actual results will be consistent with these forward-looking statements. They are made as of the date hereof and are subject to change and the Corporation assumes no obligation to revise or update them to reflect new circumstances, except as required by law. Prospective investors should not place undue reliance on forward looking statements. These factors include the inherent risks involved in the exploration for and development of crude oil and natural gas properties, the uncertainties involved in interpreting drilling results and other geological and geophysical data, fluctuating energy prices, the possibility of cost overruns or unanticipated costs or delays and other uncertainties associated with the oil and gas industry. Other risk factors could include risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities, and other factors, many of which are beyond the control of the Corporation. Realized contractual gas sales is defined as gas produced and sold plus gas revenues received from nominated take or pay contracts. CONTACT: For more information please contact: Investor Relations South America: +571.621.1747 IR-SA@canacolenergy.com Global: +1.403.561.1648 IR-GLOBAL@canacolenergy.com http://www.canacolenergy.com
Major indexes stand at or close to record highs, but some investors worry the rally that began last March has started to flag.
Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancerBalstilimab and AGEN2373 data to be presented at ASCOiNKT cell therapy Phase 1 initiated in cancer LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the first quarter of 2021. “We have delivered on multiple key initiatives since our last update and expect to achieve additional impactful milestones during the remainder of the second quarter and the rest of 2021,” said Garo Armen, PhD, Chief Executive Officer of Agenus. “Among important developments are the continuing clinical responses we are seeing with AGEN1181. We intend to advance AGEN1181 in combination with balstilimab in cancers for which current immunotherapies have shown no activity given AGEN1181’s positive clinical responses in these tumors. Treating these cancers successfully will be of substantial value to patients while potentially representing large commercial opportunities for Agenus.” Balstilimab (anti-PD-1): BLA submitted to U.S. FDA for recurrent/metastatic cervical cancer A Biologics License Application (BLA) was submitted to the U.S. Food and Drug Administration (FDA) for the accelerated approval of balstilimab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.The submission was based on an update to data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and published in an Oncogene editorial. This updated dataset includes maturation of late patient responses, with the overall data showing response rates of 20% in PD-L1 positive tumors, 15% in all tumors (PD-L1 positive and negative), and a median duration of response of 15.4 months.Data demonstrating that balstilimab is a potentially differentiated anti-PD-1 antibody will be presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting from June 4 – 8, 2021.Discussions with the FDA regarding accelerated BLA filing for balstilimab plus zalifrelimab are ongoing; additional guidance and updated response rate data will be provided upon the FDA acceptance of the balstilimab monotherapy BLA. AGEN1181 (anti-CTLA-4): Data demonstrate continued strong activity, including in tumors unresponsive to immunotherapy, as presented at AACR 2021 At the American Association for Cancer Research (AACR) annual meeting, a new partial response with AGEN1181 monotherapy was reported in the first and only melanoma patient treated to date, as well as a new conversion to complete response with AGEN1181 plus balstilimab in an ovarian cancer patient.Continued clinical activity in patients with biomarkers which indicate a poor prognosis with approved immunotherapies, including patients with microsatellite stable (MSS) tumors and melanoma, endometrial, and ovarian cancer with the low-affinity FcyRIIIA allele. No immune-mediated hypophysitis, pneumonitis, or hepatitis were reported.As of AACR 2021, a total of seven confirmed objective responses were achieved in a Phase 1/2 trial of AGEN1181 in solid tumors out of 52 evaluable patients: 2 confirmed responses among 21 treated with monotherapy, and 5 confirmed responses among 31 treated with AGEN1181 in combination with balstilimab.Phase 2 trial in colorectal cancer was initiated; registrational trials are targeted to commence in 2021 with a focus on indications enabling a rapid path to BLA submission. Further data updates expected later this year. AGEN1777 (anti-TIGIT bispecific): Phase 1 anticipated 2021 IND submission is planned for the current quarter.Phase 1 study is expected to commence in the third quarter. Intelligent cell platform: Phase 1 study ongoing with iNKT cell therapy in patients with cancer and ARDS secondary to COVID-19 Phase 1 trial in hematologic cancers was initiated; expansion into solid tumors is expected this year. Preliminary Phase 1 data for acute respiratory distress syndrome (ARDS) secondary to COVID-19 suggest iNKTs (invariant natural killer T cells) can be dosed without adverse events attributable to the therapy and may demonstrate early signals of activity. Dose escalation is expected to be completed this year with data readouts to be presented at upcoming conferences. Additional programs and initiatives continue to advance A data update on a Phase 1 trial of AGEN2373 (a CD137 agonist antibody) will be presented at the 2021 ASCO Annual Meeting.Agenus entered into a clinical collaboration with Nelum Pharmaceuticals for zalifrelimab in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line advanced pancreatic cancer. First Quarter Financial Results We ended our first quarter 2021 with a cash balance of $119 million as compared to $100 million at December 31, 2020. Cash used in operations for the three months ended March 31, 2021 was $43 million compared to $35 million for the quarter ended March 31, 2020. Net loss for the quarter ended March 31, 2021 was $54 million or $0.27 per share which includes non-cash expenses of $12 million compared to a net loss for the same period in 2020 of $45 million, or $0.31 per share which includes non-cash expenses of $3 million. We recognized revenue of $12 million and $15 million for the quarters ended March 31, 2021 and 2020, respectively, which includes revenue related to non-cash royalties earned and revenue recognized under our collaboration agreements. Select Financial Information (in thousands, except per share data) (unaudited) March 31, 2021 December 31, 2020 Cash and cash equivalents$119,366 $99,871 Three months ended March 31, 2021 2020 Revenues, research and development$1,571 $1,928 Revenues, non-cash royalty 8,484 13,156 Revenues, other 1,664 44 Total Revenue 11,719 15,128 Research and development expenses 36,677 36,363 General and administrative expenses 16,352 10,613 Cost of service revenue 1,105 - Other expense (income) (2,579) 1,243 Non-cash interest expense 15,611 13,844 Loss on modification of debt - 2,720 Non-cash contingent consideration fair value adjustment (1,044) (4,384) Net loss$(54,403) $(45,271) Net loss per share attributable to Agenus Inc. common stockholders:$(0.27) $(0.31) Cash used in operations$42,744 $34,505 Conference CallDial-in numbers: (800) 446-1671 (US) or (847) 413-3362 (International); Confirmation Number: 50150591 WebcastA live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/dbt4fxyo. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development and regulatory plans and timelines, anticipated corporate milestones, new clinical data and program updates to be presented, and the anticipated commercial launch of balstilimab. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917firstname.lastname@example.org
With that in mind, here are three great growth stocks to buy this month not despite their recent stumbles, but because of them. Last month, for the first time in seven quarters, Entegris' (NASDAQ: ENTG) reported earnings that fell short of analysts' consensus estimates. The company's Q2 guidance for earnings per share in the range of $0.77 to $0.82 on revenue of between $530 million and $545 million is more or less what analysts were modeling, and well up from year-ago earnings of $0.60 per share and sales of $448.4 million.
The "Adiponitrile Market Share, Size, Trends, Industry Analysis Report, By Application; By Production Method; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.